Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects)
1 trial -
An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants
Lacuna Pharma Pty Ltd
Helicobacter pylori infection, GERD
1 trial -
An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.
1 trial -
Bepranemab
Lacuna Pharma Pty Ltd
Progressive Supranuclear Palsy
1 trial -
Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in
Lacuna Pharma Pty Ltd
Hidradenitis suppurativa, Axial spondyloarthritis, Moderate to Severe Plaque Psoriasis, Psoriatic arthritis
1 trial -
Bioequivalence of Cladribine 10 mg from two different products
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg/mL Oral Solution in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 20 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 70 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence study of GP-IMP-001 with regards to reference product
Lacuna Pharma Pty Ltd
healthy volunteers
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources